|
Thomas P. Koestler, Ph.D., is executive vice president and president of Schering-Plough Research Institute (SPRI), the pharmaceutical research arm of Schering-Plough Corporation.
Koestler is responsible for all aspects of SPRI, including heading up the Pharmaceutical Leadership Board (PLB). The PLB guides the strategic direction of product development programs and oversees the movement of projects through the development, registration and launch phases.
He joined Schering-Plough in August 2003 and most recently was executive vice president, Global Development, SPRI. In this position, he was responsible for setting strategic direction and implementation plans for the new development organization, including worldwide clinical development, pharmaceutical sciences, global regulatory affairs and global project management.
Before joining Schering-Plough, he was senior vice president and head of global regulatory affairs for Pharmacia Corporation. Prior to joining Pharmacia, Koestler was senior vice president and global head, drug regulatory affairs, compliance assurance, clinical safety and epidemiology for Novartis. Before that appointment, he was senior director, drug regulatory affairs, at Ortho McNeil and a director of regulatory affairs at Bristol-Myers Squibb.
Koestler received his Ph.D. degree from the State University of New York (SUNY) at Buffalo, Roswell Park Memorial Institute, where he studied medicine and pathology. He holds a B.S. degree in biology from Daeman College, Amherst, N.Y.
Koestler has been published extensively in medical journals and is a member of numerous professional associations. He also is involved in community affairs and serves as vice chairman and an officer of the Children’s Specialized Hospital Foundation in Mountainside, N.J.
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its approximately 50,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.
| 